Brief: Astria Therapeutics Announces Exclusive Worldwide License Agreement With Ichnos Sciences For Ox40 Portfolio

Astria Therapeutics

11/10/2023 22:25

Oct 11 (Reuters) - Astria Therapeutics Inc  ATXS.O :
    * ASTRIA THERAPEUTICS ANNOUNCES EXCLUSIVE WORLDWIDE LICENSE
AGREEMENT WITH ICHNOS SCIENCES FOR OX40 PORTFOLIO
    * ASTRIA THERAPEUTICS INC - EXPECT TO INITIATE A PIVOTAL
PHASE 3
TRIAL IN Q1 2025, ASSUMING POSITIVE PHASE 1B/2 RESULTS
    * ASTRIA THERAPEUTICS INC - SEES AN OPPORTUNITY WITH
STAR-0310 FOR
POTENTIAL EXPANSION INTO ADDITIONAL INDICATIONS
    * ASTRIA THERAPEUTICS -DIFFERENTIATED PRECLINICAL LEAD
CANDIDATE
STAR-0310 TO BE DEVELOPED AS POTENTIAL TREATMENT FOR ATOPIC
DERMATITIS
    * ASTRIA THERAPEUTICS INC - UNDER TERMS OF LICENSE
AGREEMENT,
ASTRIA WILL PAY ICHNOS A ONE-TIME UPFRONT LICENSE FEE OF $15
MILLION
    * ASTRIA THERAPEUTICS INC - EXPECTS TO SUBMIT AN
INVESTIGATIONAL
NEW DRUG (IND) APPLICATION FOR STAR-0310 BY YEAR-END 2024
    * ASTRIA THERAPEUTICS INC - ASTRIA IS ALSO OBLIGATED TO PAY
ICHNOS
UP TO $305 MILLION IN MILESTONES
    * ASTRIA THERAPEUTICS - IF IND IS CLEARED FOR STAR-0310 BY
YEAR-END 2024, PLANS TO INITIATE A PHASE 1A CLINICAL TRIAL IN
HEALTHY SUBJECTS IN Q1 OF 2025
    * ASTRIA THERAPEUTICS INC - ANTICIPATES REPORTING INITIAL
RESULTS
FROM PHASE 1A CLINICAL TRIAL IN Q3 OF 2025
    * ASTRIA THERAPEUTICS INC - IN ADDITION, ICHNOS WILL BE
ELIGIBLE
TO RECEIVE TIERED MID-SINGLE DIGIT TO LOW-DOUBLE DIGIT ROYALTIES

Source text for Eikon:  ID:nBw118GY3a 
Further company coverage:  ATXS.O 

 ((Reuters.Briefs@thomsonreuters.com;))